Global Brain (Global Brain) has invested in Siolta Therapeutics Inc. (Siolta Therapeutics, Founder & CEO: Nikole E. Kimes, PhD), a clinical stage biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases, through its Kirin Health Innovation fund (KHIF)and its GB-VII Growth Fund Investment Limited Partnership(GB-VII).

Siolta Therapeutics leverage their deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases.

Global Brain joined the round of funding which involved participation from top tier investors, including Khosla Ventures, Marc Benioff, Seventure Partners and SymBiosis. Global Brain highly values their unique approaches and technologies of the infant gut microbiome with the inflammatory diseases, its strong management team and its high growth potential. Together with Kirin, Global Brain will continue leveraging its resources to support Siolta Therapeutics by assisting its growth in Asia and global.

Siolta Therapeuticsについて

Name
Siolta Therapeutics Inc.
Location
San Francisco, CA
Representative
Nikole E. Kimes, PhD
Founded
February, 2017
URL
https://www.sioltatherapeutics.com/

About KHIF

Name
KIRIN-GB Fund I L.P.
Fund Term
10 years
Fund Size
5 billion JPY
General Partner
Global Brain Corporation

About GB-VII

Name
GB-VII Growth Fund Investment Limited Partnership
General Partner
Global Brain Corporation

About Global Brain

Name
Global Brain Corporation
Location
Tokyo, Japan
Representative
Yasuhiko Yurimoto
Founded
January, 1998
URL
https://globalbrains.com/